P21: Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 10 sources cited

Overview

P21 is a synthetic peptide derived from the active region of ciliary neurotrophic factor (CNTF) that promotes neurogenesis in the hippocampus. It was developed to capture CNTF's neurotrophic benefits while being small enough to cross the blood-brain barrier. In mice and rats it increased neurogenesis and synaptic plasticity, and its developers report it avoids the severe side effects that stopped trials of the full-length neurotrophic factors.

Mechanism of Action

P21 (P021 in the literature) is a four-residue peptide, Ac-DGGL(A)G-NH2, carrying an adamantylated glycine that helps it cross the blood-brain barrier and resist exopeptidases. It mimics the neurotrophic signalling of CNTF by competitively inhibiting leukemia inhibitory factor (LIF) signalling and promoting the differentiation of neural progenitor cells in the hippocampal dentate gyrus. It enhances adult hippocampal neurogenesis — the birth of new neurons in one of the few brain regions where this occurs throughout life. P21 also increases dendritic complexity and synaptic density in existing neurons, improving the structural basis for memory formation. Its mechanism involves upregulation of BDNF, which in turn lowers the activity of GSK-3β, the main tau kinase. Its developers report that, unlike the full CNTF protein, it causes none of the side effects that limited the native neurotrophic factors, though no published study tests whether it spares the JAK/STAT pathway.

P21 Benefits: What the Research Shows

  • Bolognin et al. (2014) in Neurobiology of Aging showed oral P021 reduced the age-related decline in learning and memory in 22 to 24-month-old rats, with restored neurogenesis and higher BDNF
  • Studies showed P21 rescued memory deficits in an Alzheimer's disease mouse model (3xTg-AD) by promoting neurogenesis and reducing tau pathology
  • Research in Alzheimer's Research & Therapy showed P021 rescued dendritic and synaptic deficits in the hippocampus of 3xTg-AD mice, and the earlier Peptide 6 raised synapsin I, synaptophysin and MAP2 in rats
  • Thirty days of the earlier 11-mer version, Peptide 6, improved reference memory in the Morris water maze in normal adult mice
  • P021 raised BDNF expression in the hippocampus of aged rats and of 3xTg-AD mice

P21 Dosage

  • Intranasal: 50–100 mcg per nostril, once or twice daily
  • Subcutaneous: 50–200 mcg once daily
  • Cycle: 4–8 weeks on, 2–4 weeks off
  • Start at the lower end to assess cognitive response before titrating up
  • Morning administration preferred to align with peak cognitive demand periods
  • Some protocols combine intranasal and subcutaneous routes for enhanced CNS delivery
Peptide calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

P21 Side Effects & Safety

Known Side Effects

  • Headache — occasionally reported, usually mild and during the first week of use
  • Nasal irritation — with intranasal administration, mild dryness or stinging
  • Vivid dreams — reported by some users, consistent with enhanced hippocampal activity and memory consolidation during sleep
  • Overstimulation — rare reports of mental restlessness at higher doses
  • No human data at all: every published study of this peptide is in mice or rats

Safety Profile

P21 has shown a favorable safety profile in preclinical studies with no reported organ toxicity or serious adverse events in animal models at research doses. There is no human data at all, in trials or otherwise, so nothing is known about its safety in people. The theoretical concern is that promoting neurogenesis in an uncontrolled manner could have unintended consequences, though no evidence of this has emerged. It is a research compound and should be treated as such. Individuals with neurological conditions should consult a physician before use.

What to Expect

Week 1–2: Subtle cognitive improvements — slightly better focus, improved word recall. Some users report more vivid dreams as hippocampal activity increases. Weeks 3–4: More noticeable cognitive enhancement. Learning new information feels easier, and memory consolidation improves. Users often report better spatial memory and navigation. Weeks 5–8: Peak neurogenesis effects. The newly born neurons are maturing and integrating into hippocampal circuits. Cognitive benefits are most pronounced. After cessation, benefits may persist for weeks as the new neurons continue to mature and integrate.

Common Stacks

Storage & Handling

Store lyophilized P21 at -20°C for long-term storage or 2–8°C for up to 3 months. Reconstitute with bacteriostatic water for subcutaneous use or sterile saline for intranasal application. After reconstitution, refrigerate and use within 3–4 weeks. Protect from light and avoid repeated freeze-thaw cycles.

Pricing & Available Variants

$110price range
10mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

  1. Kazim SF, Blanchard J, Dai CL, et al. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2014.
  2. Bolognin S, Buffelli M, Puoliväli J, et al. Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. Neurobiol Aging. 2014.
  3. Baazaoui N, Iqbal K. Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound. Alzheimers Res Ther. 2017.
  4. Kazim SF, Iqbal K. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease. Mol Neurodegener. 2016.
  5. Khatoon S, Chalbot S, Bolognin S, et al. Elevated Tau Level in Aged Rat Cerebrospinal Fluid Reduced by Treatment with a Neurotrophic Compound. J Alzheimers Dis. 2015.
  6. Chohan MO, Li B, Blanchard J, et al. Enhancement of dentate gyrus neurogenesis, dendritic and synaptic plasticity and memory by a neurotrophic peptide. Neurobiol Aging. 2011.
  7. Bolognin S, Blanchard J, Wang X, et al. An experimental rat model of sporadic Alzheimer's disease and rescue of cognitive impairment with a neurotrophic peptide. Acta Neuropathol. 2012.
  8. Baazaoui N, Iqbal K. Prevention of Amyloid-β and Tau Pathologies, Associated Neurodegeneration, and Cognitive Deficit by Early Treatment with a Neurotrophic Compound. J Alzheimers Dis. 2017.
  9. Chohan MO, Bragina O, Kazim SF, et al. Enhancement of neurogenesis and memory by a neurotrophic peptide in mild to moderate traumatic brain injury. Neurosurgery. 2015.
  10. Baazaoui N, Iqbal K. Alzheimer's Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound. Biomolecules. 2022.

Related Peptides

Track P21 in Your Protocol

Log your P21 doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free